As new clinical trials are testing whether hypoglycemia or new antidiabetic drugs can increase immune function through AMPK-mTOR-related pathways and protect against chemotherapy cardiotoxicity, our results raise the possibility that FMD cycles by reducing glucose concentration and activating AMPK inhibit the activation of NLRP3 and NF-KB, responsible for the release of pro-inflammatory interleukins. The gene discussed is NLRP3; the disease is Hypoglycemia.